Market Position and Strategy - Public homebuilders have increased their market share from 27% in 2012 to approximately 53% in 2024[15] - The company focuses on capital efficiency in land acquisition through optioned land, land banking, joint ventures, rolling takedowns, and seller financing[45] - The company is strategically focused on driving shareholder returns through land acquisition, improved operations, and buybacks & dividends[39] Financial Performance - The company's diluted earnings per share (EPS) has grown at a compound annual growth rate (CAGR) of 28%, reaching $1501 in FY 2024[54] - The company has repurchased approximately 52% of its shares since 2016, totaling 91 million shares at an average price of $50, and has paid approximately $644 million in dividends[63] - The company's revenue from home sales increased from $6937357000 in FY 2020 to $10563332000 in FY 2024[66] - The company's return on beginning equity was 231% in FY 2024[66] Industry Trends - The new home premium has compressed from a historical 17% to 3% in 2025, making the value proposition of a new home compelling compared to a used home[23] - The median age of owner-occupied U S homes is over 40 years, compared to 32 years in 2005[27] - Housing starts have not kept pace with household growth, indicating an undersupplied market[20] Land and Operations - The company operates in 24 states and over 60 markets[33] - The company's total addressable market (TAM) consists of approximately 575000 housing transactions with buyers having income greater than $200K[73]

COVID-19 Landscape and Strategy - COVID-19 is the leading cause of hospitalizations and death from respiratory viruses in the U S, with 460,000 hospitalizations and 45,200 deaths between October 1, 2023, and June 15, 2024[7] - The company believes COVID-19 vaccines do not provide sufficient protection, with vaccine effectiveness against hospitalization for immunocompromised adults at a maximum of approximately 36% within 7-59 days of the 2023-2024 vaccine dose[19] - Monoclonal antibodies have demonstrated a significant reduction in the risk of symptomatic COVID-19, with pemivibart showing an 84-94% reduction in risk in ordinary Americans[22] - The company aims to provide Americans with a choice for COVID-19 protection through VYD2311, a monoclonal antibody with high efficacy and long duration of protection, contrasting with the reactogenic and modestly effective COVID-19 vaccines[48, 49] Pipeline and Development - Pemgarda has received emergency use authorization (EUA) from the U S FDA in March 2024 for pre-exposure prophylaxis of COVID-19 in certain immunocompromised persons[29] - VYD2311 is designed to be a high potency, long half-life monoclonal antibody for COVID-19, with an observed IM half-life of 76 days in the first-in-human trial[39, 40] - The company is planning a Phase 2/3 clinical trial for VYD2311 for the prevention of COVID-19, supported by a single, randomized, double-blind, placebo-controlled trial[29] - The company is in the discovery phase for RSV prevention and early discovery for measles and influenza prevention[29] Financials - Q2 2025 Pemgarda net product revenue was $11 8 million[66] - The company ended Q2 2025 with approximately $34 9 million in cash and cash equivalents[66]

Q2 2025 Earnings Call August 20, 2025 G1_Dallas T1 Energy _ Q2 2025 Earnings Call Pictured: Production lines at G1_Dallas T1 Energy _ Q2 2025 Earnings Call Participants and Agenda Prepared Remarks Daniel Barcelo Chairman of the Board and Chief Executive Officer Jaime Gualy Chief Operating Officer Andy Munro Chief Legal & Policy Officer ▪ Corning supply agreement ▪ Policy overview ▪ T1's OBBB compliance road map Evan Calio Chief Financial Officer Q&A Jeff Spittel EVP, Investor Relations and Corporate Develop ...

Q2 2025 Key Highlights - Hotel GMV reached RMB 26911 million[22] - Legacy-Huazhu RevPAR decreased by 38% year-over-year[12,24] - Legacy-DH RevPAR increased by 81% year-over-year[12,26] - Total number of rooms in operation increased by 183% year-over-year, reaching 1184915[12,14,21] - H Rewards members increased by 175% year-over-year, totaling 288 million[12,15,62] - Room nights booked by members increased by 288% year-over-year, exceeding 60 million[12,16] - Manachised and Franchised (M&F) revenue increased by 228% year-over-year, reaching RMB 29 billion[18,75] - Total revenue increased by 45% year-over-year, reaching RMB 64 billion[18,70] - Total Adjusted EBITDA increased by 113% year-over-year, reaching RMB 23 billion[19,70] - Adjusted Diluted EPS increased by 95% year-over-year, reaching RMB 042[19] Financial Performance - Total revenue for Q2 2025 was RMB 6426 million, a 45% increase year-over-year[18,70] - Adjusted EBITDA for Q2 2025 was RMB 2270 million, an 113% increase year-over-year[19,70] - M&F revenue for Q2 2025 was RMB 2865 million, a 228% increase year-over-year[18,75] - M&F Gross Operating Profit for Q2 2025 was RMB 1896 million, a 232% increase year-over-year[18,77] Network and Product Development - Hanting Hotels ranked No1 on the "World's Top 50 Hotel Brands" list with 378569 rooms in operation as of June 30, 2025[30,32,117] - The company is enhancing its presence in lower-tier cities[46] - The company is stepping up the development of the upper-midscale segment, with a 233% year-over-year increase in the number of upper-midscale hotels in operation and pipeline[50,51] Guidance - The company projects M&F revenue to grow 20%-24% in Q3 2025 compared to Q3 2024[101] - The company projects total revenue to grow 2%-6% in Q3 2025 compared to Q3 2024, or 4%-8% excluding DH[103]

Financial Performance - Total net revenue grew by 124% year-over-year to RMB 2,9003 million ($4049 million)[8] - Adjusted EBITDA grew by 112% year-over-year to RMB 1,3718 million ($1915 million) with a margin of 473%[8] - The company obtained RMB 4,451 million ($6213 million) of new debt financing/refinancing facilities[8] - The company raised net proceeds of $676 million in aggregate through CB and equity new issuance[8] Data Center Capacity and Utilization - New customer commitments (net) reached +14,398 sqm[8] - Total area committed increased by 81% year-over-year to 663,959 sqm[8] - Additional area utilized (net) was +16,763 sqm[8] - Total area utilized reached 479,186 sqm, a +141% year-over-year increase, resulting in a utilization rate of 775%[8] - Capacity in service reached 618,060 sqm with a total IT power of 1,326 MW[29] Backlog and Delivery - Backlog at 2Q25 was 184,773 sqm with approximately 35% scheduled for delivery in 2H25, 35% in FY26, and 30% thereafter[16] DayOne Updates - DayOne's net revenue reached $855 million, with an adjusted EBITDA of $297 million and an adjusted EBITDA margin of 347%[64] - DayOne's utilized IT power reached 213 MW[31] FY25 Business Outlook - The company projects revenue between RMB 11,290 million and RMB 11,590 million, implying a year-over-year growth of 94% - 123%[63] - Adjusted EBITDA is expected to be between RMB 5,190 million and RMB 5,390 million, representing a year-over-year increase of 64% - 105%[63] - Updated Capex (After ABS & C-REIT) is expected to be ~RMB 2,700 million, a (103%) decrease[63]

Financial Performance - Total net revenues for 2Q25 reached RMB 4,991.5 million, a 32.2% year-over-year increase[11] - Net product revenues for 2Q25 were RMB 4,558.7 million, up 34.0% year-over-year[11] - Net service revenues for 2Q25 amounted to RMB 432.8 million, reflecting a 15.4% year-over-year growth[11] - GAAP income from operations for 2Q25 was RMB 91.1 million, a quarterly high[11] - Non-GAAP income from operations for 2Q25 was RMB 121.3 million, a 28.9% year-over-year increase[11] - ATRenew repurchased 12.3 million ADSs with US$ 31.1 million during FY24 and 1H25[11] Business Updates - 1P business net product revenues increased by 34.0% year-over-year in 2Q25[13] - Excluding Apple Trade-In and international businesses, 1P business net product revenues increased by 39.2% year-over-year in 2Q25[13] - 3P business net service revenues increased by 15.4% year-over-year in 2Q25[13] - Multi-category recycling services saw a 107.1% year-over-year increase in 2Q25[13] - Transaction volumes in 2Q25 reached 10.3 million units, a 22.6% year-over-year increase[13] - The total AHS store count reached 2,092 as of June 30, 2025, a net increase of 576 year-over-year[13]

Financial Performance - Q2 2025 revenue was $1.64 billion, a decrease of 15% year-over-year[11] - Adjusted EBITDA for Q2 2025 was $472 million, a decrease of 38% year-over-year, with a 29% margin[11] - Adjusted EBIT for Q2 2025 was $149 million, a decrease of 69% year-over-year[11] - Net income for Q2 2025 was $24 million, a decrease of 94% year-over-year, resulting in a 9% margin[11] - Cash flow from operations was $441 million, a decrease of 43% year-over-year[11] Operational Highlights - Carried volume in Q2 2025 was 895K TEUs, a decrease of 6% year-over-year[17] - The average freight rate in Q2 2025 was $1,479/TEU, a decrease of 12% year-over-year[17] - Total liquidity as of June 30, 2025, was $2.87 billion[11] 2025 Guidance - The company increased the midpoints of its 2025 guidance for Adjusted EBITDA to a range of $1.8 billion to $2.2 billion[14] - The company increased the midpoints of its 2025 guidance for Adjusted EBIT to a range of $550 million to $950 million[14] Fleet and Strategy - The company operates a fleet of 123 containerships with a total capacity of 767K TEU[20] - The company's fleet includes approximately 50% newbuild and 40% LNG-powered vessels[16, 20]

Financial Performance - Auna's consolidated revenue for Q2 2025 was S/1,094 million, a decrease of 2% year-over-year (YoY), but an increase of 4% on a foreign exchange neutral (FXN) basis[19] - Adjusted EBITDA for Q2 2025 was S/241 million, a decrease of 3% YoY, but an increase of 5% FXN, with a flat margin of 211% YoY[15,17,19] - Adjusted Net Income increased significantly YoY, showing a +6x increase[46] - The Leverage Ratio remained flat at 36x[17] Segment Performance - Healthcare Services Mexico revenue in Q2 2025 was S/274 million, a decrease of 9% YoY, but an increase of 5% in local currency[25] - Healthcare Services Peru & Oncosalud Peru revenue in Q2 2025 was S/474 million, an increase of 8% YoY[29] - Healthcare Services Colombia revenue in Q2 2025 was S/346 million, a decrease of 8% YoY, but remained flat in local currency[33] Debt and Cash Flow - The company successfully offered an additional $621 million in aggregate principal amount of senior secured notes due 2029 in May 2025[54] - End-of-period cash stood at S/175 million[50] - Consolidated debt was S/3,702 million (US$1,045 million)[54,58] Operational Metrics - Oncosalud Peru plan memberships increased by 10% YoY, reaching 1,388,579 members[19,101] - Total bed capacity across the healthcare network was 2,224 beds[19]

Q2 2025 Performance & Outlook - Target's net sales decreased by 0.9% [1] - Comparable sales decreased by 1.9% [1] - GAAP and Adjusted EPS reached $2.05 [1] - Digital comparable sales increased by 4.3% [1] Growth Drivers - Same-day services grew by more than 25% [5] - Ship-to-guest services grew by more than 7% [5] - Trading cards are tracking to become a more-than-$1 billion business for Target in 2025 [15] - Double-digit net sales growth was achieved in Roundel and Target Plus marketplace [16] Investments & Strategy - The company is on track to invest about $4 billion in 2025 to support new stores, remodels, and enhancements in supply chain and technology [21] - The company is investing in 10,000+ new GenAI licenses [25]

Acquisition - Alcon will acquire STAAR Surgical for \$28 per share in cash, representing a ~59% premium to STAAR's 90-day volume-weighted average price[15] - The acquisition represents a total equity value of approximately \$1.5 billion and is expected to be funded through short- and long-term credit facilities[15] - The acquisition is expected to be accretive to core diluted EPS in year two[15] Financial Highlights (Q2 2025) - Net sales reached \$2.6 billion, a 4% increase year-over-year on a reported basis and a 3% increase in constant currency[21] - Core operating margin was 19.1%, a decrease of 70 basis points[21] - Core diluted EPS was \$0.76, compared to \$0.74 in Q2 2024[20] Financial Highlights (1H 2025) - Net sales reached \$5.0 billion[26] - Free cash flow was \$681 million[20] Product Mix (1H 2025 Sales) - Vision Care accounted for 45% (\$2.2 billion) of sales, while Surgical accounted for 55% (\$2.8 billion)[27] - Within Vision Care, contact lenses represented 62% of sales[27] - Within Surgical, consumables represented 53% of sales[27] FY 2025 Outlook (Updated) - Net sales are projected to be between \$10.3 to \$10.4 billion[64] - Core operating margin is expected to be between 19.5% to 20.5%[64] - Core diluted EPS is maintained at \$3.05 to \$3.15[64]